Endocrine Abstracts

Intrathyroidal thymic carcinoma (ITTC) is a rare thyroid malignancy. Its histology resembles that of squamous cell carcinoma (SCC) of the thyroid. However, ITTC shows a much more favorable prognosis than SCC. We analyzed the backgrounds and clinicopathological features of 10 patients who treated with ITTC in our medical center. Five patients was male, and another five was female. The average tumor size was 4mm, and it ranged from maximum 68mm to minimum 13mm. In pre-operative ...

Background: Distant metastases at diagnosis is the worst prognostic factor for disease specific survival (DSS) in sporadic medullary thyroid carcinoma (MTC). Also, lymph node metastases are negative prognostic factors both for DSS and recurrence free survival (RFS). The question whether central (N1a) and latero-cervical compartment lymph nodes metastasis (N1b), separately evaluated, can have a different impact on DSS and RFS remains to be clarified.Patie...

Objectives: Anaplastic thyroid cancer (ATC) is one of the deadliest cancers, with a median overall survival (OS) of 4 months and a disease-specific mortality of ˜100%. Although to date no effective treatment can cure the disease, some anecdotal cases achieved longer survival and very rarely the cure of the disease. Multimodal treatment with surgery, radiotherapy, multikinase inhibitors (MKI) could improve survival in ATC, particularly when surgery is not feasible.<p c...

Objectives: Active surveillance (AS) for low-risk papillary thyroid carcinoma (PTC) has been adopted as a reasonable approach to management worldwide. In our previous cross-sectional study, patients who chose AS had better mental patient-reported outcomes (PRO) compared to those who underwent immediate surgery. This prospective, longitudinal study aimed to compare PROs between patients who chose AS and those who underwent surgery, during a one-year follow-up from the time of d...

Background: Differentiated thyroid carcinoma (DTC) in children is a rare cancer, occurring in 1/100,000 children/year. In the adults a steady increase in the incidence and change in presentation of DTC has been observed over the past 30 years.Purpose: Evaluation of changes in the clinical presentation of paediatric DTC on the example of children treated in Institute of Oncology in Gliwice between 1970 and 2015.Material and methods:...

Purpose: Bone metastases (BM) are frequent in differentiated thyroid cancer (DTC). These patients may present skeletal-related events (SRE), the leading cause of DTC-related morbidity. We aimed to evaluate the clinical features, treatment approaches, and outcomes including overall survival (OS) of DTC patients with BM complicated by SRE and their evolution over time.Methods: 178 consecutive DTC patients harbouring BM were enrolled in this retrospective s...

Objectives: This study analyzed the prevalence of newly discovered anti-thyroglobulin antibody (TgAb) and its clinical significance during the follow-up period of patients with differentiated thyroid cancer.Methods: Among patients who underwent total thyroidectomy and radioactive iodine treatment between 2008 and 2022 in a single center, 184 patients (23 male, 161 female) with Tg<1ng/ml and TgAb positive (> 60 IU/mL) at least once were targeted. ...

Background: Papillary thyroid microcarcinoma (microPTC), defined as PTC measuring 10 mm or less in greatest diameter, is the most common type of thyroid cancer. MicroPTC generally has an indolent clinical course, with slow and exclusivelly intrathyroidal growth, without any significant impact on patient morbidity and mortality of patients. Sometimes, even microPTC can show lymph nodes (LNs) involvement, ranging from incidental histological findings to preoperative evidence of ...

Introduction: Papillary thyroid carcinoma (PTC) is a common thyroid gland malignancy. Postoperative suppression therapy with levothyroxine (LT4) is commonly used to prevent recurrence or progression of the disease. The optimal duration and dose of LT4 suppression therapy remain a matter of debate. The optimal duration and dose of LT4 suppression therapy remain a matter of debate, with recommendations varying based on the patient’s age, sex, tumor characteristics, and risk...